https://psychoreanimatology.org/forum/voprosy-i-repliki/6452-fda-odobrilo-novyj-preparat-vraylar-cariprazine/Recent content in FDA одобрило новый препарат Vraylar (cariprazine) on Психиатрия и психореаниматологияHugoru-RUFri, 30 Oct 2015 03:16:06 +0300Fri, 30 Oct 2015 03:16:06 +0300<p>Меня очень смущает то, что все исследования против плацебо. По сути FDA обошлось с ним как с first in class, а не стоило.</p>Thu, 29 Oct 2015 00:08:52 +0300<blockquote> <p>который продемонстрировал эффективность в облегчении негативных симптомов шизофрении, таких как отсутствие мотивации и желаний.</p> </blockquote> <p>Так и о галоперидоле писали, когда он появился.</p>Wed, 28 Oct 2015 13:10:25 +0300<p><a href="http://alert.psychnews.org/2015/09/fda-approves-vraylar-for-treatment-of.html">http://alert.psychnews.org/2015/09/fda-approves-vraylar-for-treatment-of.html</a></p> <p>FDA Approves Vraylar for Treatment of Schizophrenia and Bipolar Disorder</p> <p>The Food and Drug Administration (FDA) last week approved Vraylar (cariprazine), a dopamine D2/D3 receptor partial agonist, as a treatment for schizophrenia and bipolar disorder in adults.</p> <p>The approval was based on a set of six controlled clinical trials that included over 2,700 adults with bipolar disorder or schizophrenia. Vraylar was shown to reduce the symptoms of both disorders compared with placebo, and was fairly well tolerated, with the most commonly reported adverse reactions being extrapyramidal symptoms and restlessness (akathisia).</p>